Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.47 |
| ▸ | CDK9 | P50750 | 5/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.44 |
| ▸ | STK10 | O94804 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | GFRA3 | O60609 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913833 | 0.93 | ERN1 (0.46) | CDK2CDK9LRRK2ERN1SLK | |
| SCHEMBL2859316 | 0.83 | PDGFRB (0.51) | CDK2SLKGFRA3RETSYK | |
| SCHEMBL8614216 | 0.82 | ERN1 (0.49) | LRRK2ERN1CTSAPRMT5MAP4K4 | |
| SCHEMBL8615551 | 0.82 | ERN1 (0.49) | LRRK2ERN1CTSAPRMT5MAP4K4 | |
| SCHEMBL27756247 | 0.81 | ERN1 (0.51) | LRRK2ERN1CTSAPRMT5MAP4K4 | |
| SCHEMBL3920789 | 0.81 | LRRK2 (0.42) | CDK2CDK9LRRK2ERN1SLK | |
| SCHEMBL24363273 | 0.80 | ERN1 (0.50) | LRRK2ERN1CTSAPRMT5LMNA | |
| SCHEMBL8616560 | 0.79 | ERN1 (0.49) | LRRK2ERN1CTSAPRMT5MAP4K4 | |
| SCHEMBL8613062 | 0.78 | ERN1 (0.48) | ERN1CTSAPRMT5MAP4K4 | |
| SCHEMBL8612029 | 0.77 | ERN1 (0.52) | LRRK2ERN1CTSALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | CDK2 9/4885CDK9 416/4885LRRK2 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.